Sahm ScreenerSaudi Stock Screenerفلتر الأسهم السعودية
Home / Jamjoom Pharmaceuticals Factory Co. / 2025 Annual Results

Jamjoom Pharmaceuticals Factory Co. 2025 Annual Results

Revenue
SAR 1.50B
Net Profit
SAR 464M
EPS
SAR 6.63
Operating Cash Flow
SAR 406M

Jamjoom Pharmaceuticals Factory Co. (4015) reported full year 2025 revenue of SAR 1.50B, up 13.8% from SAR 1.32B in 2024. Net profit came in at SAR 464M, up 30.1% year on year. Earnings per share were SAR 6.63. The company generated SAR 406M in operating cash flow. All figures sourced from CMA-mandated XBRL filings on the Saudi Exchange, processed by Sahm Screener.

Earnings Quality

Of every SAR 1.00 in reported net profit, SAR 0.88 arrived as operating cash flow — indicating High quality earnings with a cash conversion ratio of 0.88.

Key Financial Metrics

Metric20252024
RevenueSAR 1.50BSAR 1.32B
Net ProfitSAR 464MSAR 357M
Net Margin30.9%27.0%
ROE27.0%23.9%
EPSSAR 6.63SAR 5.09
Total AssetsSAR 2.05BSAR 1.77B
Total EquitySAR 1.72BSAR 1.49B
Total LiabilitiesSAR 329MSAR 281M
Operating Cash FlowSAR 406MSAR 263M

Year on Year Comparison

Revenue increased by 13.8% compared to 2024. Net profit increased by 30.1%. Both revenue and profit grew — indicating expanding business.

View full company profile →
View all years:
2025202420232022202120202019

Financial data sourced from CMA-mandated XBRL filings published on the Saudi Exchange (Tadawul). Data processed and structured by Sahm Screener (sahmscreener.com). Updated nightly. Last updated: 2026-03-04.